I just read a story of die-hard entrepreneur (a biopreneur) from Singapore. His story reminds me some of my own path to success (define your own success).
Here is the story.
-----------------------------
Entrepreneurship is a 'piece of cake'
Oct 18, 2009
By Miao Fong Tian
THE recent economic crisis has brought about an entrepreneurial wave in Singapore. For Eddie Zhang, the 59-year-old founder of De Hygienique (Asia), entrepreneurship is a 'piece of cake'.
Although two of his three business ventures have failed, he continues to persevere and soldier on untiringly.
'Business failures do not mean the end of the world. They can instead help drive one to success. If my instinct tells me that certain markets are promising and possess hidden potential, then I will go for it,' said Eddie Zhang.
His only experience working for others was in the 1970s when he was working as a salesman for Inchcape, an international trading company in Singapore.
The first brand he promoted was Union Special, which was a brand of sewing machines for making jeans. Fortunately, Levis jeans had started becoming popular across the world in 1976 and they were made using sewing machines belonging to this brand. All of a sudden, business started to take off and orders came flooding in.
'The average monthly salary in Singapore at that time was $400 and my monthly salary including commissions was as much as $4,000!,' said Mr Zhang.
After earning his first 'pot of gold', Mr Zhang decided to become an entrepreneur by producing printed circuit boards for small companies in Singapore. He ultimately sold the business to an Indian company for $200,000 under the impact of the economic crisis in the 1980s. He also lived in India for three years to help the buyer set up a plant and install the relevant equipment.
After he sold the company, Mr Zhang decided to try his hand at buying and selling second hand books. He subsequently opened six book stores in Singapore called EMF. However, his businesses, along with those of other bookstores, suffered when the National Library Board established regional libraries around the island in the 1990s. Turnover plummeted by nearly 50 per cent and Mr Zhang was left with three stores.
After the Sars crisis of 2003, Mr Zhang moved into the healthcare industry.
'Healthcare is an industry for the 21st century, especially at a time where people tend to grow more fearful of death as they become more affluent,' said Mr Zhang. 'This can be seen in the increase in the number of people who take vitamins and eat organic food.'
Investing $500,000, Mr Zhang set up Mitex Hygienics, later changing the company's name to De Hygienique (Asia). The company provides professional cleaning services for household items like mattresses, furniture and carpets. At the same time, Mr Zhang hired John Chan as his general manager in charge of operations to assist him in handling the daily running of the business.
The cleaning company began with services for people's homes but has expanded its customer base to include hotels, corporations and the food and beverage (F&B) industry in 2005. De Hygienique achieved a turnover of $800,000 last year with enterprises comprising 40 per cent and households comprising 60 per cent of its business. It now employs a total of 16 people.
The arrival of the influenza A H1N1 flu in the first quarter of this year has led to a 10 per cent increase in the company's revenue from household customers. Nevertheless, De Hygienique saw a 20 to 30 per cent drop in income from corporate customers due to the recent economic crisis.
Mr Chan revealed that many corporate customers have demanded that they extend their service term or cut their fees. A number of them even cancelled their cleaning budgets altogether to cut costs.
Mr Zhang said that De Hygienique has expanded its operations into the Indonesian market and is planning to further expand its business to Hong Kong and Bangkok. He is also considering the Malaysian and Vietnamese markets.
Sunday, October 18, 2009
Thursday, October 15, 2009
Swine flu and pulmonary emboli (lung arteries blockage)
WASHINGTON (Reuters) - The new pandemic H1N1 flu may cause blood clots and other unusual damage in the lungs and doctors need to be on the lookout, U.S. researchers reported on Thursday.
Two studies published in the American Journal of Roentgenology show the need to check X-rays and CT scans for unusual features, and also point out swine flu can be tricky to diagnose in some of the sickest patients.
H1N1 flu is causing a pandemic, and while it is not particularly deadly, it is sickening many younger adults and older children who usually escape the worst effects of seasonal flu.
"It is therefore essential that clinicians be able to recognize possible cases of pandemic H1N1 influenza in high-risk groups so that they order the appropriate diagnostic tests, begin specific antiviral therapy, and prepare to provide intensive supportive measures as needed," Dr. Daniel Mollura of the National Institutes of Health Clinical Center in Maryland and colleagues wrote.
One middle-aged man who died was not diagnosed until after death, but unusual findings on his X-rays may be able to help doctors save other, similar patients.
Mollura's team found irregularities called ground-glass opacities in the patient's lungs using a CT scan. Although the patient was severely ill and had a fever, he tested negative for flu and doctors did not treat him for it.
The man died five days after he went into the hospital and the autopsy confirmed he had swine flu. The lung lesions seen on his CT scan matched lung damage done by the virus, Mollura and colleagues said.
In another study in the same journal, CT scans of patients with severe cases of swine flu showed many had pulmonary emboli, which block the arteries in the lungs, a team at the University of Michigan found.
Anticoagulant drugs can break up these clots and save lives.
Dr. Prachi Agarwal and colleagues examined 66 patients diagnosed with H1N1, 14 of them who were in the intensive care unit. All 66 got standard X-rays, which can show if a patient has pneumonia.
They performed enhanced X-rays known as computed tomography or CT scans on 15 of the patients, 10 of them who were in the ICU on ventilators to help them breathe. Five of the ICU patients had the blood clots in the lungs, Agarwal reported
"Our study suggests that patients who are severely ill with H1N1 are also at risk for developing pulmonary emboli, which should be carefully sought for on contrast-enhanced CT scans," Agarwal said in a statement.
"The majority of patients undergoing chest X-rays with H1N1 have normal radiographs (X-rays)," she added. Pulmonary emboli are also not normally seen in flu, she said.
"CT scans proved valuable in identifying those patients at risk of developing more serious complications as a possible result of the H1N1 virus, and for identifying a greater extent of disease than is appreciated on chest radiographs."
(Reporting by Maggie Fox; Editing by Julie Steenhuysen and Cynthia Ostemran)
Two studies published in the American Journal of Roentgenology show the need to check X-rays and CT scans for unusual features, and also point out swine flu can be tricky to diagnose in some of the sickest patients.
H1N1 flu is causing a pandemic, and while it is not particularly deadly, it is sickening many younger adults and older children who usually escape the worst effects of seasonal flu.
"It is therefore essential that clinicians be able to recognize possible cases of pandemic H1N1 influenza in high-risk groups so that they order the appropriate diagnostic tests, begin specific antiviral therapy, and prepare to provide intensive supportive measures as needed," Dr. Daniel Mollura of the National Institutes of Health Clinical Center in Maryland and colleagues wrote.
One middle-aged man who died was not diagnosed until after death, but unusual findings on his X-rays may be able to help doctors save other, similar patients.
Mollura's team found irregularities called ground-glass opacities in the patient's lungs using a CT scan. Although the patient was severely ill and had a fever, he tested negative for flu and doctors did not treat him for it.
The man died five days after he went into the hospital and the autopsy confirmed he had swine flu. The lung lesions seen on his CT scan matched lung damage done by the virus, Mollura and colleagues said.
In another study in the same journal, CT scans of patients with severe cases of swine flu showed many had pulmonary emboli, which block the arteries in the lungs, a team at the University of Michigan found.
Anticoagulant drugs can break up these clots and save lives.
Dr. Prachi Agarwal and colleagues examined 66 patients diagnosed with H1N1, 14 of them who were in the intensive care unit. All 66 got standard X-rays, which can show if a patient has pneumonia.
They performed enhanced X-rays known as computed tomography or CT scans on 15 of the patients, 10 of them who were in the ICU on ventilators to help them breathe. Five of the ICU patients had the blood clots in the lungs, Agarwal reported
"Our study suggests that patients who are severely ill with H1N1 are also at risk for developing pulmonary emboli, which should be carefully sought for on contrast-enhanced CT scans," Agarwal said in a statement.
"The majority of patients undergoing chest X-rays with H1N1 have normal radiographs (X-rays)," she added. Pulmonary emboli are also not normally seen in flu, she said.
"CT scans proved valuable in identifying those patients at risk of developing more serious complications as a possible result of the H1N1 virus, and for identifying a greater extent of disease than is appreciated on chest radiographs."
(Reporting by Maggie Fox; Editing by Julie Steenhuysen and Cynthia Ostemran)
Wednesday, October 7, 2009
Nobel Prize - 2009
It is very exciting to see so much happiness in a camp of RNA-world. this year four friends got Nobel Prizes (2009) - Elizabeth Blackburn, Jack Szostak, Tom Steitz and Venkatraman Ramakrishnan - Everyone from the RNA World.
During my tenure at the University of Colorado, Boulder at the Prof. Olke C. Uhlenbeck's group I had the opportunities to meet most these top scientists along with many other in the RNA-world who are equally contributing to the understanding of sciences and in making human life better.
It is a very happy day for all of us - RYAN
During my tenure at the University of Colorado, Boulder at the Prof. Olke C. Uhlenbeck's group I had the opportunities to meet most these top scientists along with many other in the RNA-world who are equally contributing to the understanding of sciences and in making human life better.
It is a very happy day for all of us - RYAN
Saturday, June 27, 2009
Bioprenerus: The Molecular Millionaires
California Takshila University just launched the Book titled Biopreneurs: The Molecular Millionaires at a LARTA-NIH Conference at San Jose, California held on June 25, 2009. Mr. Rohit K. Shukla, CEO of LARTA, introduced the book to a packed audience of biotech, pharma, and Governmental executives.
Book is available at the
www.biopreneur.org
and at the University press
http://www.ctuniv.org/university-press.htm
Thank you,
-----------------------------------------------------------------------------------
Biopreneurs from the title on, is well-structured four main sections, the reader is smoothly driven in a dynamic and convincing way to understand the interactions of the scientific aspects of biotechnology with legal, political, regulatory and even ethical approaches required to make biotechnology a commercial success.
Indeed, the opening chapters introduce readers to the real concept of applied biotechnology, defined not only as a product or service making one, but also as a mixture of technologies that altogether and in harmony allow the development of a long-lasting commercial biotechnology.
Particularly noticeable is the clarifying chapters on various issues and the differentiation between the interwined concepts normally associated with the issue of intellectual property. Next, the author dives the reader into corporate biotechnology, highlighting the requirements to establish a biotechnology company.
This is a pivotal issue for pure-science biotechnologists, regularly deprived of the required background to build-up from bench to market. The last section is a well-organized basic tour through relevant issues that get together science and technology as a functional unit. It clearly shows the reader that being successful in biotechnology is not an easy task, but not impossible either if the proper steps are followed. Notwithstanding, one of the key concepts resulting from reading the book is that of optimism.
Biotechnology has destroyed paradigms, created new ones and reborn others, always with a positive slope, selling the feeling that we are just at the beginning of a never-ending process. Dr. Ryan Baidya is an enthusiast. Through the different sections of his book he speeds up to convince the reader that getting into Biotechnology is a must. In summary, a robust, commercially-oriented readable book which should be read not only by specialists but also by entrepreneurs which foresee Biotechnology as the business of tomorrow.
Book is available at the
www.biopreneur.org
and at the University press
http://www.ctuniv.org/university-press.htm
Thank you,
-----------------------------------------------------------------------------------
Biopreneurs from the title on, is well-structured four main sections, the reader is smoothly driven in a dynamic and convincing way to understand the interactions of the scientific aspects of biotechnology with legal, political, regulatory and even ethical approaches required to make biotechnology a commercial success.
Indeed, the opening chapters introduce readers to the real concept of applied biotechnology, defined not only as a product or service making one, but also as a mixture of technologies that altogether and in harmony allow the development of a long-lasting commercial biotechnology.
Particularly noticeable is the clarifying chapters on various issues and the differentiation between the interwined concepts normally associated with the issue of intellectual property. Next, the author dives the reader into corporate biotechnology, highlighting the requirements to establish a biotechnology company.
This is a pivotal issue for pure-science biotechnologists, regularly deprived of the required background to build-up from bench to market. The last section is a well-organized basic tour through relevant issues that get together science and technology as a functional unit. It clearly shows the reader that being successful in biotechnology is not an easy task, but not impossible either if the proper steps are followed. Notwithstanding, one of the key concepts resulting from reading the book is that of optimism.
Biotechnology has destroyed paradigms, created new ones and reborn others, always with a positive slope, selling the feeling that we are just at the beginning of a never-ending process. Dr. Ryan Baidya is an enthusiast. Through the different sections of his book he speeds up to convince the reader that getting into Biotechnology is a must. In summary, a robust, commercially-oriented readable book which should be read not only by specialists but also by entrepreneurs which foresee Biotechnology as the business of tomorrow.
Sunday, March 1, 2009
BT-brinjal: damages liver, pancreas, intestinal and even inter-generational
India shouldn't approve Bt brinjal: Analyst
Press Trust Of India / Mumbai March 02, 2009, 0:09 IST
Genetically modified (GM) food, including the latest Bt Brinjal, affects human health in various ways and should not be approved by India, latest studies have confirmed.
“Bt Brinjal, like many other GM crops, has recently been shown by independent analysis to impact health adversely,” a well-known food and trade analyst Devinder Sharma said here.
When GM food was tested on rats, the results were alarming and should not be allowed to enter India,” Sharma, from the Delhi-based Forum for Food Security and Biotechnolgy, said.
“The evidence linked GM food showed stunted growth, impaired immune systems, damages to liver, pancreas, intestinal and even inter-generational effects. Latest studies have confirmed that GM foods affect fertility as well,” he added.
If the consumers do not raise their voices and question the decision, to be taken by the Genetic Engineering Approval Committee (GEAC) to approve Bt brinjal (genetically modified using a gram positive soil swelling bacteria Bacillus thuringiensis), it would create health problems, he cautioned.
“Normal brinjal and the Bt variety will have similar appearance and you may not be able to distibgusih it. You will not be able to exercise your informed choice of not eating Bt brinjal,” Sharma cautioned.
Also, the GEAC is considering the approval of Bt brinjal merely on the data provided by the company and has not asked for any independent or long-term testing or verification; nor have they consulted farmers or consumers, he said.
The idea of the genetic modification is to make the brinjal generate its own toxin so that insects and pests.
Press Trust Of India / Mumbai March 02, 2009, 0:09 IST
Genetically modified (GM) food, including the latest Bt Brinjal, affects human health in various ways and should not be approved by India, latest studies have confirmed.
“Bt Brinjal, like many other GM crops, has recently been shown by independent analysis to impact health adversely,” a well-known food and trade analyst Devinder Sharma said here.
When GM food was tested on rats, the results were alarming and should not be allowed to enter India,” Sharma, from the Delhi-based Forum for Food Security and Biotechnolgy, said.
“The evidence linked GM food showed stunted growth, impaired immune systems, damages to liver, pancreas, intestinal and even inter-generational effects. Latest studies have confirmed that GM foods affect fertility as well,” he added.
If the consumers do not raise their voices and question the decision, to be taken by the Genetic Engineering Approval Committee (GEAC) to approve Bt brinjal (genetically modified using a gram positive soil swelling bacteria Bacillus thuringiensis), it would create health problems, he cautioned.
“Normal brinjal and the Bt variety will have similar appearance and you may not be able to distibgusih it. You will not be able to exercise your informed choice of not eating Bt brinjal,” Sharma cautioned.
Also, the GEAC is considering the approval of Bt brinjal merely on the data provided by the company and has not asked for any independent or long-term testing or verification; nor have they consulted farmers or consumers, he said.
The idea of the genetic modification is to make the brinjal generate its own toxin so that insects and pests.
Sunday, February 15, 2009
BARACK OBAMA ON STEM CELL
BARACK OBAMA ON STEM CELL
BARACK OBAMA IS A CHAMPION OF STEM CELL RESEARCH
Barack Obama believes we owe it to the American public to explore the potential
of stem cells to treat the millions of people su ering from debilitating and lifethreatening diseases. Stem cells hold the promise of treatments and cures for
more than 70 major diseases and conditions such as Parkinson’s and Alzheimer’s
disease, spinal cord injuries, and diabetes. As many as 100 million Americans may
benefit from embryonic stem cell research. As president, Obama would:
Promote Embryonic Stem Cell Research
Embryonic stem cells remain unmatched in their potential for treatment of a wide variety of diseases and health conditions. Obama has been a long-term supporter of greater stem cell research. He introduced legislation in the Illinois Senate that specifically permitted embryonic stem cell research in Illinois.
Support Medical Advancement and Innovation
Restrictions on federal funding for stem cell research have led top researchers in the field to move to other countries. Obama believes every American should have access to potential new cures. He supports greater federal government funding on a wider array of stem cell lines.
Expand the Number of Stem Cell Lines Available for Research
There are over 400,000 embryos being stored in facilities throughout the United States, the majority of which are reserved for infertile couples. However, many of these embryos will go unused, destined for permanent storage in a freezer or disposal. Obama is a cosponsor of legislation that would allow research on more stem cells derived from embryos donated for in vitro fertilization.
Ensure Ethical Standards
Obama understands stem cell research needs to be conducted with the highest ethical standards. Obama introduced legislation in the Illinois Senate to ensure that only those embryos that would otherwise be discarded could be used and that donors would have to provide written consent for the use of the embryos.
BARACK OBAMA IS A CHAMPION OF STEM CELL RESEARCH
Barack Obama believes we owe it to the American public to explore the potential
of stem cells to treat the millions of people su ering from debilitating and lifethreatening diseases. Stem cells hold the promise of treatments and cures for
more than 70 major diseases and conditions such as Parkinson’s and Alzheimer’s
disease, spinal cord injuries, and diabetes. As many as 100 million Americans may
benefit from embryonic stem cell research. As president, Obama would:
Promote Embryonic Stem Cell Research
Embryonic stem cells remain unmatched in their potential for treatment of a wide variety of diseases and health conditions. Obama has been a long-term supporter of greater stem cell research. He introduced legislation in the Illinois Senate that specifically permitted embryonic stem cell research in Illinois.
Support Medical Advancement and Innovation
Restrictions on federal funding for stem cell research have led top researchers in the field to move to other countries. Obama believes every American should have access to potential new cures. He supports greater federal government funding on a wider array of stem cell lines.
Expand the Number of Stem Cell Lines Available for Research
There are over 400,000 embryos being stored in facilities throughout the United States, the majority of which are reserved for infertile couples. However, many of these embryos will go unused, destined for permanent storage in a freezer or disposal. Obama is a cosponsor of legislation that would allow research on more stem cells derived from embryos donated for in vitro fertilization.
Ensure Ethical Standards
Obama understands stem cell research needs to be conducted with the highest ethical standards. Obama introduced legislation in the Illinois Senate to ensure that only those embryos that would otherwise be discarded could be used and that donors would have to provide written consent for the use of the embryos.
Sunrise on Stem-cell research in USA
Politepreneur(R) President Barack Obama is to lift ban on stem cell research. According to the White house aide, the president will shortly issue an executive order to lift an eight-year ban embryonic stem cell research imposed by the President George W. Bush.
Former president Bush reduced federal funding for stem cell research in 2001. Embryonic stem cells are the most basic human cells which can develop into any type of cell in the body and is a new frontier in advancing human health care.
This is one of the promise that the president Obama made during his presidential campaign and in his inaugural address last month he again promised to return scientific research on the right track for human health.
Food and Drug Administration (FDA) already have taken steps forward in advancing stem-cell related drug/cure developments. FDA last month cleared the way for the first trial to see if human embryonic stem cells could treat people safely.
Ryan Baidya
California Takshila University
Former president Bush reduced federal funding for stem cell research in 2001. Embryonic stem cells are the most basic human cells which can develop into any type of cell in the body and is a new frontier in advancing human health care.
This is one of the promise that the president Obama made during his presidential campaign and in his inaugural address last month he again promised to return scientific research on the right track for human health.
Food and Drug Administration (FDA) already have taken steps forward in advancing stem-cell related drug/cure developments. FDA last month cleared the way for the first trial to see if human embryonic stem cells could treat people safely.
Ryan Baidya
California Takshila University
Saturday, February 14, 2009
Biotech and Obama-Stimulus package
Politepreneur(R)-President Barack Obama President Barack Obama, savoring his first major victory in Congress, said Saturday that newly passed $787 billion economic stimulus legislation marks a "major milestone on our road to recovery."
Speaking in his weekly radio and Internet address, Obama said, "I will sign this legislation into law shortly, and we'll begin making the immediate investments necessary to put people back to work doing the work America needs done."
One of the key areas is to see great advancement and job creation is the Life-sciences sector. President also received a multimillion dollars-ok for his IT-health care projects.
Following article describes potential boom in the biotech/pharma sector.
--------------------------------------------------
Scientists see boom for biotechnology
by Jean-Louis Santini
CHICAGO (AFP) – The promising potential of biotechnology remains largely unused, especially in such crucial areas as healthcare and production of environmentally friendly fuels, scientists said.
The experts gathered here at an annual conference of the American Association for the Advancement of Science predicted that biotechnology was likely to experience a boom in coming years.
"What you have seen over the last 35 years of biotech are tremendous applications, immediate applications of biotech starting with recombinant therapeutics all the way through," said Drew Endy, assistant professor of bioengineering at Stanford University.
He said the phenomenon can be explained by the fact that no one thus far has even "scratched the surface" of the promising science.
But Endy argued that science was moving forward fast. In only six years, he said, the gene sequencing project went from reading a bacteria genome to reading a human genome.
Last year, researchers at the Venter Institute built a bacteria genome from scratch, he noted.
"I bet we will be able to construct a human chromosome, and the yeast genome," Endy said, offering a six-year forecast. "It sounds a little bit crazy because it's an exponential improvement in the tools."
He said there were lots of opportunities to take those tools forward.
"We are advocating now a national initiative in synthetic biology that would include in part a route map for getting better in building genetic material, constructing DNA from scratch and assembling it into genes and genomes," the scientist pointed out.
Jay Keasling, professor of biochemical engineering at the University of California at Berkeley, said his project was using a microbe in order to produce a drug while significantly reducing its cost.
"We anticipate in one or two years that the optimization process will be completed and that production of the drug will commence and have it in the hands of people in Africa shortly thereafter," Keasling said.
Meanwhile, Christina Smolke, assistant professor of bioengineering at Stanford University spoke about her efforts to design molecules that go into the cell and analyse the cellular state before delivering a therapeutic effect.
"Our goal is to make more effective therapies by taking advantage of the natural capabilities of our immune system and introducing slight modifications in cases where it is not doing what we would like it to do," she said.
Smolke said she hoped to translate her technologies into intelligent cellular therapeutics for glioma cancer patients in the next five years.
"That's a very optimistic view ...but so far things are moving quickly," she pointed out.
-----------------------------------------------
Source: AP (Associated Press)
http://news.yahoo.com/s/afp/20090214/sc_afp/ussciencebiotechnology_20090214122650
Speaking in his weekly radio and Internet address, Obama said, "I will sign this legislation into law shortly, and we'll begin making the immediate investments necessary to put people back to work doing the work America needs done."
One of the key areas is to see great advancement and job creation is the Life-sciences sector. President also received a multimillion dollars-ok for his IT-health care projects.
Following article describes potential boom in the biotech/pharma sector.
--------------------------------------------------
Scientists see boom for biotechnology
by Jean-Louis Santini
CHICAGO (AFP) – The promising potential of biotechnology remains largely unused, especially in such crucial areas as healthcare and production of environmentally friendly fuels, scientists said.
The experts gathered here at an annual conference of the American Association for the Advancement of Science predicted that biotechnology was likely to experience a boom in coming years.
"What you have seen over the last 35 years of biotech are tremendous applications, immediate applications of biotech starting with recombinant therapeutics all the way through," said Drew Endy, assistant professor of bioengineering at Stanford University.
He said the phenomenon can be explained by the fact that no one thus far has even "scratched the surface" of the promising science.
But Endy argued that science was moving forward fast. In only six years, he said, the gene sequencing project went from reading a bacteria genome to reading a human genome.
Last year, researchers at the Venter Institute built a bacteria genome from scratch, he noted.
"I bet we will be able to construct a human chromosome, and the yeast genome," Endy said, offering a six-year forecast. "It sounds a little bit crazy because it's an exponential improvement in the tools."
He said there were lots of opportunities to take those tools forward.
"We are advocating now a national initiative in synthetic biology that would include in part a route map for getting better in building genetic material, constructing DNA from scratch and assembling it into genes and genomes," the scientist pointed out.
Jay Keasling, professor of biochemical engineering at the University of California at Berkeley, said his project was using a microbe in order to produce a drug while significantly reducing its cost.
"We anticipate in one or two years that the optimization process will be completed and that production of the drug will commence and have it in the hands of people in Africa shortly thereafter," Keasling said.
Meanwhile, Christina Smolke, assistant professor of bioengineering at Stanford University spoke about her efforts to design molecules that go into the cell and analyse the cellular state before delivering a therapeutic effect.
"Our goal is to make more effective therapies by taking advantage of the natural capabilities of our immune system and introducing slight modifications in cases where it is not doing what we would like it to do," she said.
Smolke said she hoped to translate her technologies into intelligent cellular therapeutics for glioma cancer patients in the next five years.
"That's a very optimistic view ...but so far things are moving quickly," she pointed out.
-----------------------------------------------
Source: AP (Associated Press)
http://news.yahoo.com/s/afp/20090214/sc_afp/ussciencebiotechnology_20090214122650
Subscribe to:
Posts (Atom)
